484 related articles for article (PubMed ID: 32431692)
1. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.
Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A
Front Immunol; 2020; 11():613. PubMed ID: 32431692
[TBL] [Abstract][Full Text] [Related]
2. Short- and Long-Lived Autoantibody-Secreting Cells in Autoimmune Neurological Disorders.
Zografou C; Vakrakou AG; Stathopoulos P
Front Immunol; 2021; 12():686466. PubMed ID: 34220839
[TBL] [Abstract][Full Text] [Related]
3. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.
Topakian R; Zimprich F; Iglseder S; Embacher N; Guger M; Stieglbauer K; Langenscheidt D; Rath J; Quasthoff S; Simschitz P; Wanschitz J; Windisch D; Müller P; Oel D; Schustereder G; Einsiedler S; Eggers C; Löscher W
J Neurol; 2019 Mar; 266(3):699-706. PubMed ID: 30649616
[TBL] [Abstract][Full Text] [Related]
4. A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression.
Koneczny I; Mané-Damas M; Zong S; De Haas S; Huda S; van Kruining D; Damoiseaux J; De Rosa A; Maestri M; Guida M; Molenaar P; Van Damme P; Fichtenbaum A; Perkmann T; De Baets M; Lazaridis K; Zouvelou V; Tzartos S; Ricciardi R; Losen M; Martinez-Martinez P
Front Immunol; 2024; 15():1325171. PubMed ID: 38715598
[TBL] [Abstract][Full Text] [Related]
5. Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab.
Weger S; Appendino JP; Clark IH
J Binocul Vis Ocul Motil; 2019; 69(1):26-29. PubMed ID: 30811277
[TBL] [Abstract][Full Text] [Related]
6. Is MuSK myasthenia gravis linked to IgG4-related disease?
Raibagkar P; Ferry JA; Stone JH
J Neuroimmunol; 2017 Apr; 305():82-83. PubMed ID: 28284351
[TBL] [Abstract][Full Text] [Related]
7. Long-lasting treatment effect of rituximab in MuSK myasthenia.
Díaz-Manera J; Martínez-Hernández E; Querol L; Klooster R; Rojas-García R; Suárez-Calvet X; Muñoz-Blanco JL; Mazia C; Straasheijm KR; Gallardo E; Juárez C; Verschuuren JJ; Illa I
Neurology; 2012 Jan; 78(3):189-93. PubMed ID: 22218276
[TBL] [Abstract][Full Text] [Related]
8. Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody.
Zhou Y; Yan C; Gu X; Zhou L; Lu J; Zhu W; Huan X; Luo S; Zhong H; Lin J; Lu J; Zhao C; Xi J
Muscle Nerve; 2021 Jun; 63(6):824-830. PubMed ID: 33745138
[TBL] [Abstract][Full Text] [Related]
9. IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients.
Koneczny I; Stevens JA; De Rosa A; Huda S; Huijbers MG; Saxena A; Maestri M; Lazaridis K; Zisimopoulou P; Tzartos S; Verschuuren J; van der Maarel SM; van Damme P; De Baets MH; Molenaar PC; Vincent A; Ricciardi R; Martinez-Martinez P; Losen M
J Autoimmun; 2017 Feb; 77():104-115. PubMed ID: 27965060
[TBL] [Abstract][Full Text] [Related]
10. Association between musk antibody concentrations and the myasthenia gravis composite score in 3 patients: A marker of relapse?
Triplett JD; Hardy TA; Riminton DS; Chu SYK; Reddel SW
Muscle Nerve; 2019 Sep; 60(3):307-311. PubMed ID: 31177576
[TBL] [Abstract][Full Text] [Related]
11. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients.
Illa I; Diaz-Manera J; Rojas-Garcia R; Pradas J; Rey A; Blesa R; Juarez C; Gallardo E
J Neuroimmunol; 2008 Sep; 201-202():90-4. PubMed ID: 18653247
[TBL] [Abstract][Full Text] [Related]
12. Relation of HLA-DRB1 to IgG4 autoantibody and cytokine production in muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG).
Çebi M; Durmuş H; Yılmaz V; Yentür SP; Aysal F; Oflazer P; Parman Y; Deymeer F; Saruhan-Direskeneli G
Clin Exp Immunol; 2019 Aug; 197(2):214-221. PubMed ID: 30929252
[TBL] [Abstract][Full Text] [Related]
13. Laboratory Investigation of Hybrid IgG4 k/λ in MuSK Positive Myasthenia Gravis.
Basile U; Napodano C; Gulli F; Pocino K; Di Santo R; Todi L; Basile V; Provenzano C; Ciasca G; Marino M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502051
[TBL] [Abstract][Full Text] [Related]
14. MuSK-Ab positive myasthenia: not always grave.
Zouvelou V; Stamboulis E; Skriapa L; Tzartos SJ
J Neurol Sci; 2013 Aug; 331(1-2):150-1. PubMed ID: 23706725
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in AChR subtype of myasthenia gravis: systematic review.
Di Stefano V; Lupica A; Rispoli MG; Di Muzio A; Brighina F; Rodolico C
J Neurol Neurosurg Psychiatry; 2020 Apr; 91(4):392-395. PubMed ID: 32098874
[TBL] [Abstract][Full Text] [Related]
16. Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis.
Stathopoulos P; Kumar A; Nowak RJ; O'Connor KC
JCI Insight; 2017 Sep; 2(17):. PubMed ID: 28878127
[TBL] [Abstract][Full Text] [Related]
17. Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients.
Basile U; Marino M; Napodano C; Pocino K; Alboini PE; Gulli F; Evoli A; Provenzano C; Bartoccioni E
J Immunol Res; 2018; 2018():9646209. PubMed ID: 29765992
[TBL] [Abstract][Full Text] [Related]
18. Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis.
Plomp JJ; Huijbers MG; van der Maarel SM; Verschuuren JJ
Ann N Y Acad Sci; 2012 Dec; 1275():114-22. PubMed ID: 23278586
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease.
Vakrakou AG; Karachaliou E; Chroni E; Zouvelou V; Tzanetakos D; Salakou S; Papadopoulou M; Tzartos S; Voumvourakis K; Kilidireas C; Giannopoulos S; Tsivgoulis G; Tzartos J
Front Immunol; 2023; 14():1212757. PubMed ID: 37564637
[TBL] [Abstract][Full Text] [Related]
20. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1.
Niks EH; van Leeuwen Y; Leite MI; Dekker FW; Wintzen AR; Wirtz PW; Vincent A; van Tol MJ; Jol-van der Zijde CM; Verschuuren JJ
J Neuroimmunol; 2008 Mar; 195(1-2):151-6. PubMed ID: 18384886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
